William M. Mitchell, M.D., Ph.D., was appointed Chairman of the board of Hemispherx Biopharma, Inc., in February 2016 after serving as a director since July 1998. Dr. Mitchell is a professor of pathology, microbiology and immunology at Vanderbilt University School of Medicine and is a board-certified physician. Dr. Mitchell earned an M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as House Officer in Internal Medicine — Osler Service — followed by a fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews and abstracts that relate to the pathogenesis of obligate intracellular pathogens, innate and adaptive immune responses, and liquid biopsy cancer — chromosomal instability — diagnostics. He is the inventor or co-inventor of 14 issued U.S. patents as well as derivative foreign patents. Dr. Mitchell has worked with many professional societies that have included the American Society of Investigative Pathology, or ASIP; the International Society for Antiviral Research, or ISAR; the American Society of Biochemistry and Molecular Biology, or ASBMB; the American Society of Microbiology, or ASM; the American Chemical Society, or ACS; and the American Society of Clinical Oncology, or ASCO. Dr. Mitchell is a member of the American Medical Association, or AMA. He has served on numerous review committees for the National Institutes of Health, or NIH; the Centers for Disease Control, or CDC; the European Union, or EU; and the College of American Pathology, or CAP. He is an independent director of Chronix Biomedical, a genetics-based cancer diagnostic company.
